GlobeNewswire

Shorter GMAT Exam Launches on April 16

Dela
Candidate-Friendly Change Designed to Enhance Test-Taking Experience
 
RESTON, Va., April 04, 2018 (GLOBE NEWSWIRE) -- The Graduate Management Admission Council (GMAC) is shortening the length of the GMAT exam by 30 minutes as part of its ongoing focus on creating the best possible testing experience and offering user-friendly features. The new, shorter exam - 3.5 hours instead of 4 - will be available for test-takers worldwide beginning April 16. 

The quality of the exam remains unchanged in terms of reliability, validity, security and integrity. GMAT scores before and after this change will be the same and comparable across time.

"We are always looking for ways to help build candidate confidence and streamline the test experience, all with one goal in mind-to help GMAT test-takers do their very best on exam day," said Vineet Chhabra, senior director of product management for GMAC. "We believe candidates will have less anxiety and feel better prepared, which can contribute to a better reflection of their true performance on the exam."

The time savings are achieved by streamlining the two longer sections of the exam, the Quantitative and Verbal Reasoning sections, reducing the number of unscored, research questions in these sections. Several tutorial and instruction screens that test-takers see at the test center have also been simplified. There are no changes to the exam's Analytical Writing or Integrated Reasoning sections. The way the GMAT exam is scored, the content of the exam, the question types and the average time per question are not changing.

"Through our ongoing market feedback and operational reviews, we were able to identify this opportunity to shorten the exam, without changing its reliability," said Chhabra. "This change will not affect GMAT exam scoring as the number of scored questions will not change. The scoring algorithm will be the same; the Total Score and individual Quantitative and Verbal section scores will be comparable to the exams taken prior to this change. There is no action or change required on the part of business schools and universities. We are providing candidates with a better testing experience, while providing business schools with the same high quality, fair and reliable scores."

Along with these changes, GMAC is providing a new, online tutorial that mimics the screens that test-takers see on exam day, further enhancing and streamlining the test center experience. By moving the tutorial information online, to www.mba.com/, test takers can access it prior to arriving at the test center, at their convenience and as often as they wish.

The GMAT exam is designed to showcase the skills that are most relevant to the world's leading graduate business programs; 9 out of 10 new MBA enrollments globally are made using a GMAT score. 

To align with the changes, GMAC is launching new GMAT Official Prep tools to match the structure of the shorter exam. The GMAT Official Practice Exams and Practice Questions will be available on an online platform for better ease-of-use, as well as some feature improvements such as single sign-on and ability to access prep materials across multiple devices. GMAT Official Prep tools are the only official source of retired GMAT questions, and the Council's research shows that candidates who use official products score an average of 18 percent higher on the GMAT exam than those who don't. The updated practice tools will be available by the end of April.    

These changes are part of a series of candidate-friendly enhancements to the GMAT exam in recent years, all focused on improving the testing experience, including: 

  • Exam section order selection at the testing center (Select Section Order)
  • Making unofficial scores available immediately, before leaving the test center following the exam
  • Updates to score cancellation and reinstatement options

To learn more about these changes, please review our FAQs: http://www.mba.com/global/frequently-asked-questions/shorter-gmat-exam

About GMAC: The Graduate Management Admission Council (GMAC) is a global, non-profit association of 223 leading graduate business schools. Founded in 1953, we are actively committed to advancing the art and science of admissions by convening and representing the industry and offering best-in-class products and services for schools and students. GMAC owns and administers the Graduate Management Admission Test® (GMAT®) exam, used by more than 7,000 graduate programs worldwide. Other GMAC assessments include the NMAT by GMAC(TM) exam, for entrance into graduate management programs in India and South Africa, and the Executive Assessment, specifically designed for Executive MBA programs around the world. The Council is based in the United States with offices in London, New Delhi (Gurugram), and Hong Kong. For information on assessments, study tools and services for candidates, visit www.mba.com. For information about The Council and our market intelligence, professional development opportunities and services for graduate management education, please visit www.gmac.com.

MEDIA CONTACT: Tania Hernandez-Andersen, GMAC Sr. Dir. of Corporate Brand Communications, thernandez-andersen@gmac.com or 703-668-9638 (office), 571-294-4059 (mobile).




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Graduate Management Admission Council via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Oboya participates in China International Import Expo1.11.2018 15:00Pressmeddelande

Newsletter Lerum, 1th November 2018 Oboya Horticulture Industries AB (publ) ("Oboya"), a global manufacturer and supplier of products and services for the cultivation industry, will participate in China International Import Expo in Shanghai, China. China International Import Expo (CIIE) is a six-day fair held from November 5 to November 10, 2018 at the National Convention & Exhibition Center in Shanghai, China. This fair brings together companies, exhibitors and professional buyers from all over the world. The fair creates new channels for companies from different countries and regions and provides the opportunity to do business, strengthen cooperation and promote trade. Oboya's strategy is to work globally in the various markets in the cultivation and flower industry, which it's important for Oboya to participate in the major trade shows. Oboya has its own booth at the fair and will show/marketing the European cultivation products and technology to the Chinese market. The purpose of t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum